Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate
These findings indicate that mecbotamab vedotin has the potential to be a robust and less toxic therapeutic agent, offering promise as a treatment for patients with AXL-positive cancers.
Authors
- Charles Xing (ORCID: https://orcid.org/0000-0002-5108-3577)
- Hwai Wen Chang (ORCID: https://orcid.org/0000-0001-8666-2002)
- Jay M. Short (ORCID: https://orcid.org/0000-0001-7661-6854)
- Gerhard Frey (ORCID: https://orcid.org/0000-0003-2086-4853)
- William J. Boyle (ORCID: https://orcid.org/0000-0001-5304-5649)
- Jian Chen (ORCID: https://orcid.org/0000-0001-8105-3670)
- Haizhen Liu (ORCID: https://orcid.org/0000-0002-6268-5485)
- Jing Wang (ORCID: https://orcid.org/0009-0005-3735-734X)
Institutions
- BioAtla (United States) (US)
Publication Details
- Journal
- Antibody Therapeutics
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1093/abt/tbaf006
- Citations
- 5
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 3.99